Data from an Oxford University lab study has confirmed that a three-dose course of AstraZenecas Covid vaccine is effective against the Omicron variant of the prevailing coronavirus.
According to Reuters, the development was announced by the pharmaceutical company on Thursday.
Findings from the study are similar to those of Pfizer and Moderna who also found that a third jab works against Omicron.
Oxford University researchers that carried out the study were different from the ones who worked on producing the AstraZeneca vaccine.
“As we better understand Omicron, we believe we will find that T-cell response provides durable protection against severe disease and hospitalisations,” Mene Pangalos, the head of AstraZeneca’s biopharmaceuticals R&D said.
He was referring to a critical component of the immune system that respond to fight infection.
Antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from Covid-19, the Anglo-Swedish drugmaker added.
